Atossa Therapeutics, Inc.
ATOS · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $14,117 | $17,334 | $15,083 | $9,210 |
| G&A Expenses | $13,504 | $14,043 | $12,608 | $11,311 |
| SG&A Expenses | $13,504 | $14,043 | $12,608 | $11,311 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $27,621 | $31,377 | $27,691 | $20,521 |
| Operating Income | -$27,621 | -$31,377 | -$27,691 | -$20,521 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $2,117 | $1,283 | $731 | -$85 |
| Pre-Tax Income | -$25,504 | -$30,094 | -$26,960 | -$20,606 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$25,504 | -$30,094 | -$26,960 | -$20,606 |
| % Margin | – | – | – | – |
| EPS | -0.2 | -0.24 | -0.21 | -0.18 |
| % Growth | 16.7% | -14.3% | -16.7% | – |
| EPS Diluted | -0.2 | -0.24 | -0.21 | -0.18 |
| Weighted Avg Shares Out | 125,859 | 126,081 | 126,624 | 116,950 |
| Weighted Avg Shares Out Dil | 125,859 | 126,081 | 126,624 | 116,950 |
| Supplemental Information | – | – | – | – |
| Interest Income | $4,050 | $4,343 | $877 | $6 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $17 | $23 | $8 | $23 |
| EBITDA | -$27,604 | -$31,354 | -$27,683 | -$20,498 |
| % Margin | – | – | – | – |